Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Dr Nirmalya Roy Moulik
Eligibility
Inclusion criteria
Inclusion criteria: 1) Diagnosis of relapsed ALL 2) Age more than 15 years at the time of relapse of ALL 3) Treatment on TMH-R-ALL 2018 protocol
Exclusion criteria
Exclusion criteria: 1) High risk relapse patients where HSCT is not feasible (due to social/financial/donor unavailability issues) 2) Patient getting palliated upfront. 3) Not consenting for enrolment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the 3-year event free survival (EFS) of children treated on TMH-R-ALL 18 protocol.Timepoint: End of each block of standard chemotherapy and after completion of the treatment, at 6 months for 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To estimate the incidence and nature of severe (grade 3-4) toxicities during various phases (7 chemotherapy blocks and maintenance) of treatment. 2. To estimate the proportion of patients clearing minimal residual disease (MRD) post block-1 chemotherapy in standard, intermediate and high risk groups. Timepoint: End of each block of standard chemotherapy and after completion of the treatment, at 6 months for 3 years | — |
Countries
India
Contacts
Public ContactDr Nirmalya Roy Moulik
Tata memorial Hospital
Outcome results
None listed